Alprazolam
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Alprazolam
- Alprazolam: From Anxiety and Panic Disorder to Insomnia
Alprazolam: From Anxiety and Panic Disorder to Insomnia
One-Sentence Summary
Alprazolam is a short-to-intermediate-acting triazolo-benzodiazepine internationally recognised for the management of anxiety disorders and panic disorder, though it currently holds no MHRA marketing authorisation in the United Kingdom. The TxGNN model predicts it may also be effective for insomnia, supported by observational and comparative clinical evidence assessed at Level 3, with a recommendation to proceed with guardrails given the well-characterised but risk-laden hypnotic mechanism. Notably, this multi-indication analysis also identifies agoraphobia as a predicted indication carrying Level 1 evidence from multiple large randomised controlled trials — the highest-priority repurposing finding in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorders and panic disorder (internationally recognised use; no current MHRA marketing authorisation) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L3 |
| UK Market Status | Not currently marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why Is This Prediction Reasonable?
Alprazolam acts as a positive allosteric modulator of the GABA-A receptor complex. By binding to the benzodiazepine recognition site, it increases the frequency of chloride ion channel opening in response to GABA, thereby enhancing inhibitory neurotransmission across the cerebral cortex and limbic system. This mechanism underlies its anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant properties.
The hypnotic application of this mechanism is well established: alprazolam reduces sleep onset latency and increases Stage 2 (light) sleep, explaining its historical use as a sleep aid — particularly in patients with comorbid anxiety. Clinical trials have used alprazolam as an active comparator in sleep disorder studies (e.g., versus melatonin in haemodialysis patients), and observational data from patients with coronary heart disease and comorbid insomnia confirm a measurable hypnotic effect. However, alprazolam suppresses both REM sleep and slow-wave (deep) sleep — both essential for cognitive restoration and memory consolidation. Tolerance develops rapidly, and discontinuation commonly triggers rebound insomnia, reinforcing a cycle of escalating use.
Within the current UK clinical framework, the insomnia repurposing case is mechanistically credible but clinically restricted. Current NICE guidance recommends cognitive behavioural therapy for insomnia (CBT-I) as the preferred first-line treatment, with short-term Z-drugs (e.g., zopiclone 3.75–7.5 mg) as pharmacological second-line. Benzodiazepines sit further down this hierarchy and carry a significantly less favourable long-term safety profile. The most clinically defensible niche for alprazolam in insomnia would be in patients with significant comorbid anxiety where a single agent might address both presentations simultaneously, or in specific populations where Z-drugs are contraindicated (e.g., severe hepatic impairment, some renal replacement therapy patients).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02648776 | Observational | Unknown | 1,400 | Prospective cohort study assessing patterns, efficacy, and safety of hypnotic agents (including benzodiazepines) in elderly patients with sleep disorders at a Taiwanese academic medical centre; evaluates pharmacokinetic, pharmacogenetic, and clinical outcomes |
| NCT00266409 | Phase 4 | Completed | 418 | Eight-week multicentre open-label RCT comparing Niravam™ (alprazolam orally disintegrating tablet) combined with a newly prescribed SSRI or SNRI versus SSRI/SNRI alone in GAD or panic disorder; sleep disturbance is a plausible secondary outcome in this anxiety population |
Four further trials were retrieved but excluded: NCT04572750 focused on facilitating benzodiazepine cessation (negative reference only); NCT01146600 assessed clarithromycin for hypersomnia and is wholly unrelated to alprazolam; NCT01893632 tested gabapentin for benzodiazepine dependence and was terminated with only two participants enrolled; NCT03327506 compared hypnosis to alprazolam as a pre-operative anxiolytic with no insomnia endpoint and an unknown status.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33403184 | 2020 | Comparative RCT | Cureus | Alprazolam versus melatonin for sleep disturbances in end-stage renal disease patients on haemodialysis; alprazolam used as active comparator; addresses subjective and objective sleep quality in a population where Z-drugs may be inappropriate |
| 36692463 | 2023 | Meta-analysis | Acta Pharmaceutica | Systematic review and meta-analysis of tranquilisers (including benzodiazepines) in elderly patients with chronic non-communicable diseases; assesses optimal dose, efficacy outcomes, and adverse effects |
| 39183410 | 2024 | Observational Study | Medicine | 116-patient study in coronary heart disease with comorbid insomnia; alprazolam used as the active control group; assesses cardiac function and serum neurotransmitter levels under treatment |
| 37801512 | 2023 | Mechanistic (Pre-clinical) | Aging | Proteomic analysis in mice after 24-day repeated alprazolam administration; 439 differentially expressed hippocampal proteins identified, linking mitochondrial dysfunction to memory impairment — a directly relevant long-term cognitive safety signal for hypnotic use |
| 23330992 | 2013 | Review | Expert Opinion on Drug Metabolism & Toxicology | Pharmacokinetic review of anxiolytics including benzodiazepines; relevant to dosing interval and drug interaction considerations when repurposing for insomnia management |
| 37984023 | 2024 | Epidemiological Model | Value in Health Regional Issues | Ten-year predictive model of benzodiazepine prescribing trends; highlights long-term population-level risks including cognitive impairment, potential Alzheimer’s disease association, dependence, and falls in elderly patients |
UK Market Information
Alprazolam does not hold any active MHRA marketing authorisation and is absent from the BNF as a licensed medicinal product in the United Kingdom. It is classified as a Schedule 4 Part 1 controlled drug under the Misuse of Drugs Regulations 2001, meaning it may be prescribed on a standard (non-controlled drug) prescription but must be stored appropriately as a controlled substance. Any clinical use in the UK would require prescribing as an unlicensed medicine; named-patient import authorisation is available under Regulation 167 of the Human Medicines Regulations 2012 where there is a clinical need that cannot be met by a licensed alternative.
No UK marketing authorisations are currently held for this drug.
Safety Considerations
Please refer to the Summary of Product Characteristics (SmPC) and the BNF for full safety information. Suspected adverse reactions should be reported via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).
Additional Predicted Indications
1. Agoraphobia — Evidence Level: L1 | Recommended Decision: Proceed with Guardrails
TxGNN Prediction Score: 99.56%
Agoraphobia commonly occurs in the context of panic disorder (Panic Disorder with Agoraphobia, PDA). Alprazolam’s GABA-A positive modulation reduces hyperexcitability in the amygdala and broader fear circuitry, attenuating panic attacks and thereby diminishing the anticipatory anxiety and avoidance behaviour that define agoraphobia. This is the most extensively investigated psychiatric indication for alprazolam and carries the strongest evidence base of any predicted indication in this evidence pack.
Clinical Trials:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01330472 | Phase 1 | Completed | 16 | Single-dose crossover bioequivalence study of Xanax XR 3 mg manufactured at two sites; confirms alprazolam extended-release is in active clinical development for anxiety-spectrum indications including panic disorder with agoraphobia |
| NCT00634790 | Phase 4 | Terminated | 49 | Open-label assessment of alprazolam XR safety, tolerability, and population pharmacokinetics in adolescents with panic disorder or anxiety with panic attacks, with or without agoraphobia; limited by early termination |
Literature Evidence:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38014714 | 2023 | Cochrane Network Meta-analysis | Cochrane Database of Systematic Reviews | Comprehensive network meta-analysis of pharmacological treatments for panic disorder in adults; the most current high-quality synthesis positioning alprazolam within the contemporary evidence base |
| 3282478 | 1988 | Multicenter Phase 3–equivalent RCT | Archives of General Psychiatry | Landmark 8-week placebo-controlled flexible-dose trial (n=526); alprazolam 2–10 mg/day significantly superior to placebo for agoraphobia with panic attacks — cornerstone efficacy evidence |
| 3282479 | 1988 | Multicenter RCT — Discontinuation Phase | Archives of General Psychiatry | Discontinuation phase (n=126); significant symptom worsening during 4-week taper despite gradual withdrawal — a critical dependence and withdrawal safety signal |
| 8101126 | 1993 | Cross-national Controlled RCT | British Journal of Psychiatry | Cross-national trial (London and Toronto, n=154); alprazolam 5 mg/day versus placebo combined with or without exposure therapy; includes six-month treatment-free follow-up |
| 2651490 | 1989 | 3-arm Double-blind RCT | Journal of Clinical Psychopharmacology | n=55; double-blind comparison of alprazolam, propranolol, and placebo; supports alprazolam efficacy; propranolol was not effective in this population |
| 21869686 | 2011 | Meta-analysis | Journal of Clinical Psychopharmacology | Meta-analysis of 8 RCTs (n≥631) comparing alprazolam versus other benzodiazepines for panic disorder and agoraphobia; no statistically significant difference in class-level efficacy |
| 7802851 | 1994 | Controlled Safety Study | British Journal of Psychiatry | Characterises the side-effect and adverse event profile of alprazolam versus placebo specifically in panic disorder with agoraphobia — a directly UK-relevant publication |
| 3358644 | 1988 | Multicenter RCT — Safety Report | Archives of General Psychiatry | Safety, tolerability, and patient acceptance data from the n=525 multicenter trial; mean daily dose 5.7 mg characterised |
| 9259039 | 1997 | Long-term Follow-up | Psychotherapy and Psychosomatics | 3.5-year post-treatment follow-up documenting long-term outcomes and durability of response after alprazolam and/or exposure therapy in agoraphobia and panic disorder |
| 2859580 | 1985 | Comparative Clinical Review | Psychiatric Clinics of North America | Early landmark review of MAOIs and alprazolam for panic disorder and agoraphobia; includes practical clinical prescribing guidance |
2. Benign Paroxysmal Torticollis of Infancy (BPTI) — Evidence Level: L5 | Recommended Decision: Hold
TxGNN Prediction Score: 99.61%
No clinical trials or published literature were identified for alprazolam in this indication. The mechanistic hypothesis — that GABA-A enhancement might reduce vestibular nucleus hyperexcitability in a condition linked to CACNA1A calcium channel dysfunction and migraine precursor mechanisms — is entirely theoretical. The calcium channel pathway implicated in BPTI is distinct from the GABA-A mechanism targeted by alprazolam, and the connection remains unvalidated in either animal models or human studies. The near-complete absence of benzodiazepine safety data in infants further precludes any clinical consideration at this stage. This prediction should be treated as hypothesis-generating only.
Conclusion and Next Steps
Insomnia (Primary Predicted Indication, L3)
Decision: Proceed with Guardrails
Rationale: Alprazolam’s GABA-A-mediated hypnotic mechanism is well characterised, and observational and comparative clinical data support efficacy for sleep disturbance — particularly in patients with comorbid anxiety or in populations where Z-drugs may be contraindicated. However, significant safety concerns (dependence, tolerance, rebound insomnia, REM suppression, cognitive impairment, and falls risk in elderly patients) and the absence of a UK marketing authorisation require this indication to be pursued within a carefully defined and monitored clinical framework.
To proceed, the following is needed:
- Identification of a clearly defined target patient subgroup (e.g., insomnia with comorbid anxiety disorder; or insomnia in end-stage renal disease where Z-drugs are inappropriate)
- Head-to-head randomised clinical trial versus current UK standard of care (CBT-I and/or zopiclone) with pre-specified primary and safety endpoints, including dependence liability
- Full pharmacovigilance plan addressing cognitive adverse effects, tolerance, withdrawal, and falls risk — with particular focus on elderly patients
- Complete mechanism of action (MOA) documentation to address the current data gap
- MHRA pre-submission meeting to clarify the marketing authorisation pathway for an unlicensed medicine in the UK
Agoraphobia (Second Predicted Indication, L1) — Recommended Priority
Decision: Proceed with Guardrails
Rationale: Multiple Phase 3–equivalent multicentre RCTs (individual trial sizes up to n=526) and a 2023 Cochrane network meta-analysis establish robust Level 1 evidence for alprazolam in panic disorder with agoraphobia. This represents the most compelling repurposing finding in this evidence pack and should be prioritised in any clinical development programme. The primary barriers are dependence liability and the absence of a current UK licence; positioning relative to SSRIs (currently first-line per NICE guidance) and structured psychological therapies must be clearly addressed.
To proceed, the following is needed:
- MHRA pre-submission meeting to discuss a marketing authorisation strategy for panic disorder with agoraphobia in the UK
- Updated safety data package addressing dependence, withdrawal syndrome, and long-term cognitive effects to current MHRA/EMA standards
- NICE health technology appraisal positioning alprazolam relative to SSRIs, SNRIs, and CBT for panic disorder
- Risk minimisation strategy (RMS) addressing controlled drug status, prescribing governance, and dependence liability
Benign Paroxysmal Torticollis of Infancy (L5)
Decision: Hold. No supporting clinical or pre-clinical evidence exists. This prediction is hypothesis-generating only and cannot be developed further without mechanistic validation and paediatric safety data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.